Resmed Inc RSMDF
We take great care to ensure that the data presented and summarized in this overview for RESMED INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RSMDF
Top Purchases
Top Sells
About RSMDF
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Insider Transactions at RSMDF
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 24
2024
|
Carol Burt Director |
SELL
Bona fide gift
|
Indirect |
47
-0.31%
|
-
|
May 15
2024
|
Jan De Witte Director |
SELL
Open market or private sale
|
Direct |
360
-4.57%
|
$78,480
$218.29 P/Share
|
May 15
2024
|
Peter C Farrell Director |
SELL
Bona fide gift
|
Direct |
68,200
-43.33%
|
-
|
May 08
2024
|
Brett Sandercock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,000
-12.37%
|
$2,743,000
$211.37 P/Share
|
May 08
2024
|
Brett Sandercock Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+10.25%
|
$1,212,000
$101.64 P/Share
|
May 07
2024
|
Michael J. Farrell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,683
-3.22%
|
$3,171,528
$216.5 P/Share
|
May 07
2024
|
Michael J. Farrell Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,683
+1.57%
|
$1,233,372
$84.98 P/Share
|
Apr 29
2024
|
Carol Burt Director |
SELL
Bona fide gift
|
Indirect |
234
-1.54%
|
-
|
Apr 29
2024
|
Karen Drexler Director |
SELL
Open market or private sale
|
Direct |
425
-4.79%
|
$90,950
$214.92 P/Share
|
Mar 04
2024
|
Michael J Rider Global General Counsel |
SELL
Open market or private sale
|
Direct |
81
-1.21%
|
$14,580
$180.0 P/Share
|
Mar 01
2024
|
Michael J Rider Global General Counsel |
SELL
Open market or private sale
|
Direct |
200
-2.9%
|
$34,600
$173.25 P/Share
|
Feb 22
2024
|
Peter C Farrell Director |
SELL
Open market or private sale
|
Direct |
10,935
-6.5%
|
$1,990,170
$182.66 P/Share
|
Nov 27
2023
|
Brett Sandercock Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.13%
|
$456,000
$152.62 P/Share
|
Nov 22
2023
|
Michael J Rider Global General Counsel |
SELL
Bona fide gift
|
Direct |
72
-1.03%
|
-
|
Nov 20
2023
|
Robert Andrew Douglas Special Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,375
-9.03%
|
$203,500
$148.94 P/Share
|
Nov 20
2023
|
Kaushik Ghoshal President, SaaS Business |
SELL
Payment of exercise price or tax liability
|
Direct |
366
-2.76%
|
$54,168
$148.94 P/Share
|
Nov 20
2023
|
Michael J. Farrell Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,352
-0.53%
|
$348,096
$148.94 P/Share
|
Nov 16
2023
|
Jan De Witte Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,768
+18.33%
|
-
|
Nov 16
2023
|
Richard Sulpizio Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,768
+9.57%
|
-
|
Nov 16
2023
|
Harjit Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,768
+16.49%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 40.4K shares |
---|---|
Exercise of conversion of derivative security | 60.7K shares |
Payment of exercise price or tax liability | 16.6K shares |
---|---|
Open market or private sale | 83.9K shares |
Bona fide gift | 68.6K shares |